TCRX vs. OCGN, LXEO, CCCC, REPL, VYGR, EDIT, FATE, TSHA, SLDB, and AURA
Should you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Ocugen (OCGN), Lexeo Therapeutics (LXEO), C4 Therapeutics (CCCC), Replimune Group (REPL), Voyager Therapeutics (VYGR), Editas Medicine (EDIT), Fate Therapeutics (FATE), Taysha Gene Therapies (TSHA), Solid Biosciences (SLDB), and Aura Biosciences (AURA). These companies are all part of the "biological products, except diagnostic" industry.
Ocugen (NASDAQ:OCGN) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings.
In the previous week, Ocugen and Ocugen both had 31 articles in the media. TScan Therapeutics' average media sentiment score of 0.45 beat Ocugen's score of -0.10 indicating that Ocugen is being referred to more favorably in the media.
Ocugen has a beta of 3.49, indicating that its stock price is 249% more volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.
Ocugen has higher earnings, but lower revenue than TScan Therapeutics. Ocugen is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ocugen has a net margin of 0.00% compared to Ocugen's net margin of -653.50%. Ocugen's return on equity of -61.13% beat TScan Therapeutics' return on equity.
10.3% of Ocugen shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 3.5% of Ocugen shares are held by insiders. Comparatively, 2.8% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Ocugen received 79 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 74.19% of users gave TScan Therapeutics an outperform vote while only 68.92% of users gave Ocugen an outperform vote.
Ocugen presently has a consensus target price of $4.67, indicating a potential upside of 143.06%. TScan Therapeutics has a consensus target price of $12.00, indicating a potential upside of 30.58%. Given TScan Therapeutics' higher possible upside, research analysts plainly believe Ocugen is more favorable than TScan Therapeutics.
Summary
Ocugen beats TScan Therapeutics on 9 of the 16 factors compared between the two stocks.
Get TScan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TScan Therapeutics Competitors List
Related Companies and Tools
